Please assess the completion status of the following clinical trial:

Trial Title: Leptin to Treat Lipodystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~All ethnic groups.~Males and females.~* Age greater than or equal to 6 months.~* Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient.~Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period.~Presence of at least one of the following metabolic abnormalities:~1. Presence of diabetes as defined by the 2007 ADA criteria~   1. Fasting plasma glucose greater than or equal to 126 mg/dL, or~  2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or~  3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl~2. Fasting insulin greater than 30 micro units/ml.~3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants)~   -Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.~   EXCLUSION CRITERIA:~   Pregnant women, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.~   Exclusions for underlying diseases likely to increase side effects or hinder objective data collection:~  * Known infectious liver disease~  * Known HIV infection~  * Current alcohol or substance abuse~  * Psychiatric disorder impeding competence or compliance~  * Active tuberculosis~  * Use of anorexiogenic drugs~  * Other condition(s) which in the opinion of the clinical investigators would impede completion of the study~  * Subjects who have known hypersensitivity to E. Coli derived proteins.~  * Subjects with acquired lipodystrophy and a hematologic abnormality such as neutropenia and/or lymphadenopathy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metreleptin (Type: EXPERIMENTAL): subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).